Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Efficiency and Risk Factors for CMV Transmission in Seronegative Hematopoietic Stem Cell Recipients

5 Mar 2012

Abstract excerpt

Cytomegalovirus (CMV) transmission via stem cells or marrow in CMV donor seropositive/recipient seronegative (D+/R-) hematopoietic cell transplantation (HCT) is surprisingly inefficient, and factors associated with transmission in these high-risk HCT recipients are unknown. In a retrospective cohort of D+/R- HCT recipients, cumulative incidence curve estimates were used to determine posttransplantation rates of...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Cytomegalovirus and herpesvirus research
Share to Hematopoietic Stem Cell Transplantation
Share to Herpesvirus Infections and Treatments

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 22387334
DOI: 10.1016/j.bbmt.2012.02.008

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 6 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Efficiency and Risk Factors for CMV Transmission in Seronegative Hematopoietic Stem Cell RecipientsPMID 22387334Read ↗

Emerging concepts in cytomegalovirus infection following hematopoietic stem cell transplantationSemantic proximity Read ↗

Epidemiology, clinical outcomes, and treatment patterns of cytomegalovirus infection after allogeneic hematopoietic stem cell transplantation in China: a scoping review and meta-analysisSemantic proximity Read ↗

Letermovir for primary and secondary cytomegalovirus prevention in allogeneic hematopoietic cell transplant recipients: Real‐world experienceSemantic proximity Read ↗

American Society for Transplantation and Cellular Therapy Series #11: Updated Cytomegalovirus Guidelines in Hematopoietic Cell Transplant and Cellular Therapy RecipientsSemantic proximity Read ↗

Donor Cytomegalovirus Status Influences the Outcome of Allogeneic Stem Cell Transplant: A Study by the European Group for Blood and Marrow TransplantationSemantic proximity Read ↗

How I treat CMV reactivation after allogeneic hematopoietic stem cell transplantationSemantic proximity Read ↗

An assessment of donor-to-recipient transmission patterns of human cytomegalovirus by analysis of viral genomic variants.Semantic proximity Read ↗

Letermovir at a Prophylactic Dose for Cytomegalovirus Infection in Children Undergoing Allogeneic Hematopoietic Stem Cell Transplantation: A Single-Center Retrospective Study in JapanSemantic proximity Read ↗

Human Cytomegalovirus Seroprevalence and Titres in Solid Organ Transplant Recipients and Transplant Donors in Seoul, South KoreaSemantic proximity Read ↗

Cytomegalovirus resistance in CD34+ -selected hematopoietic cell transplant recipients.Semantic proximity Read ↗

HLA-DRB1*09 is associated with increased incidence of cytomegalovirus infection and disease after allogeneic hematopoietic stem cell transplantation.Semantic proximity Read ↗

Viral reactivations following hematopoietic stem cell transplantation in pediatric patients – A single center 11-year analysisSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.